:::
With the advent of aging society, cancers have topped the list of causes of death in Taiwan for 25 years in a row. Breast cancer currently has the highest of all cancer incidence rates among women all over the world. In 2006 breast cancer ranked fourth place on the list of causes of death among women in Taiwan, and colorectal cancer had the third biggest number of sufferers among all main prevalent cancers of the world. The Institute of Nuclear Energy Research, Nuclear Safety Commission (Abbreviated as INER), has been actively conducting research and development of medicine for cancer diagnosis an treatment in recent years. It has set the goal of providing assistance to the public for their health protection, so as to foster nuclear medicine technology in the country and support the nuclear medicine industry.
With the development of cancer molecular biology and genomics, there have been new findings in the diagnosis and treatment of cancer. How to directly block the growth and accretion of cancerous cells without harming or damaging normal cells is a new trend in cancer treatment. Targeted therapy is one of the common methods of treatment. It directly damages targets (cancerous cells). Assisted by monoclonal antibodies having excessive reaction to the surface of cancerous cells and special affinity to special surface antigens, monoclonal antibodies are able to enter cells and incorporate with such special antigens, thus triggering the immune system and destroying cancerous cells to achieve the purpose of treatment.
Currently the institute is conducting research on the application of radioimmunoagents for cancers such as breast cancer and colorectal cancer. These agents are urgently needed in Taiwan. Taking breast cancer as an example, the research aims to incorporate monoclonal antibodies with 188Re-SOCTA/HYNIC - Herceptin, which are of special characteristics of isotopes. It has been proved on animals that there is obvious accumulation of this medicine in cancerous cells. In addition, gamma and beta radioactive rays released from 188Re also have the capability of diagnosing and treating cancers. This medicine is the latest radioimmunoagent developed in the world and provides a new hope for breast cancer patients in treatment. The institute has also completed systematic animal body analysis on nuclear medicine 188Re-BMEDA/ Liposome, which is used for the treatment of colorectal cancer, and has been confirmed to have fairy good potentials in cancer diagnosis and treatment. The medicine will provide a new opportunity for colorectal cancer patients to be diagnosed and treated at early stages.
The institute has been actively devoted to R & D and promotion of application of radiological biomedicine. It has been focused on the development of radiopharmaceuticals for the diagnosis and treatment of major illnesses in Taiwan. The institute has also established cooperation with domestic and foreign medical research institutes in the hope to understand the latest moves and progress in the research and development of radiopharmaceuticals as well as medical needs. thereby meeting the needs of hospitals in Taiwan on diagnosis and treatment, and enhancing health care capability in Taiwan.
Research and Development of Nuclear Medicine for Diagnosis and Treatment of Cancer--Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan Paying Attention to the health of Countrymen--(20080317)
Last Update: May 14, 2020
With the advent of aging society, cancers have topped the list of causes of death in Taiwan for 25 years in a row. Breast cancer currently has the highest of all cancer incidence rates among women all over the world. In 2006 breast cancer ranked fourth place on the list of causes of death among women in Taiwan, and colorectal cancer had the third biggest number of sufferers among all main prevalent cancers of the world. The Institute of Nuclear Energy Research, Nuclear Safety Commission (Abbreviated as INER), has been actively conducting research and development of medicine for cancer diagnosis an treatment in recent years. It has set the goal of providing assistance to the public for their health protection, so as to foster nuclear medicine technology in the country and support the nuclear medicine industry.
With the development of cancer molecular biology and genomics, there have been new findings in the diagnosis and treatment of cancer. How to directly block the growth and accretion of cancerous cells without harming or damaging normal cells is a new trend in cancer treatment. Targeted therapy is one of the common methods of treatment. It directly damages targets (cancerous cells). Assisted by monoclonal antibodies having excessive reaction to the surface of cancerous cells and special affinity to special surface antigens, monoclonal antibodies are able to enter cells and incorporate with such special antigens, thus triggering the immune system and destroying cancerous cells to achieve the purpose of treatment.
Currently the institute is conducting research on the application of radioimmunoagents for cancers such as breast cancer and colorectal cancer. These agents are urgently needed in Taiwan. Taking breast cancer as an example, the research aims to incorporate monoclonal antibodies with 188Re-SOCTA/HYNIC - Herceptin, which are of special characteristics of isotopes. It has been proved on animals that there is obvious accumulation of this medicine in cancerous cells. In addition, gamma and beta radioactive rays released from 188Re also have the capability of diagnosing and treating cancers. This medicine is the latest radioimmunoagent developed in the world and provides a new hope for breast cancer patients in treatment. The institute has also completed systematic animal body analysis on nuclear medicine 188Re-BMEDA/ Liposome, which is used for the treatment of colorectal cancer, and has been confirmed to have fairy good potentials in cancer diagnosis and treatment. The medicine will provide a new opportunity for colorectal cancer patients to be diagnosed and treated at early stages.
The institute has been actively devoted to R & D and promotion of application of radiological biomedicine. It has been focused on the development of radiopharmaceuticals for the diagnosis and treatment of major illnesses in Taiwan. The institute has also established cooperation with domestic and foreign medical research institutes in the hope to understand the latest moves and progress in the research and development of radiopharmaceuticals as well as medical needs. thereby meeting the needs of hospitals in Taiwan on diagnosis and treatment, and enhancing health care capability in Taiwan.
